{"filing":{"accession_number":"0001104659-26-111665","cik":"0001971387","ticker":"LIMNW","company_name":"Liminatus Pharma, Inc.","form":"8-K","filing_date":"2026-09-29","report_date":"2026-09-24","primary_document":"tm2626488d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926111665/tm2626488d1_8k.htm"},"events":[{"id":35654,"run_id":32850,"accession_number":"0001104659-26-111665","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.94,"summary":"Liminatus Pharma regained compliance with Nasdaq's minimum bid price rule (Listing Rule 5550(a)(2)) following a reverse stock split and transfer to The Nasdaq Capital Market. The company had previously received a notice of non-compliance on January 15, 2026, was transferred to Nasdaq Capital Market on August 4, 2026, and received notice of regained compliance on September 24, 2026.","company_name":"Liminatus Pharma, Inc.","ticker":"LIMNW","filing_date":"2026-09-29","form":"8-K","submitted_at":null,"items":[{"id":39795,"accession_number":"0001104659-26-111665","item_number":"3.01","item_title":"Notice of Delisting or Failure to","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a delisting-related matter under Item 3.01. Although the Company ultimately regained compliance with Nasdaq's minimum bid price rule (Listing Rule 5550(a)(2)) following a reverse stock split and transfer to The Nasdaq Capital Market, the core event is the Company's prior non-compliance with the bid price requirement, transfer to a lower-tier market, and the resolution of that delisting risk. The disclosure of the January 15, 2026 notice of non-compliance, the August 4, 2026 transfer to Nasdaq Capital Market, and the September 24, 2026 notice of regained compliance all constitute material delisting-related events that would affect a reasonable investor's assessment of the registrant's continued listing status.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T13:16:50.768785+00:00","company_name":"","ticker":null,"filing_date":""},{"id":39796,"accession_number":"0001104659-26-111665","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"The disclosure announces that Liminatus Pharma has regained compliance with Nasdaq's minimum bid price rule after previously failing to meet the $1.00 threshold on The Nasdaq Global Market and being transferred to The Nasdaq Capital Market. While the news is positive (compliance regained), the underlying event—the company's prior non-compliance and transfer to a lower-tier market—is a material delisting risk event. The filing documents the resolution of a listing threat that would materially affect investor assessment of the company's continued exchange listing status.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T13:16:50.768785+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39795,"accession_number":"0001104659-26-111665","item_number":"3.01","item_title":"Notice of Delisting or Failure to","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses a delisting-related matter under Item 3.01. Although the Company ultimately regained compliance with Nasdaq's minimum bid price rule (Listing Rule 5550(a)(2)) following a reverse stock split and transfer to The Nasdaq Capital Market, the core event is the Company's prior non-compliance with the bid price requirement, transfer to a lower-tier market, and the resolution of that delisting risk. The disclosure of the January 15, 2026 notice of non-compliance, the August 4, 2026 transfer to Nasdaq Capital Market, and the September 24, 2026 notice of regained compliance all constitute material delisting-related events that would affect a reasonable investor's assessment of the registrant's continued listing status.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T13:16:50.768785+00:00","company_name":"Liminatus Pharma, Inc.","ticker":"LIMNW","filing_date":"2026-09-29"},{"id":39796,"accession_number":"0001104659-26-111665","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"The disclosure announces that Liminatus Pharma has regained compliance with Nasdaq's minimum bid price rule after previously failing to meet the $1.00 threshold on The Nasdaq Global Market and being transferred to The Nasdaq Capital Market. While the news is positive (compliance regained), the underlying event—the company's prior non-compliance and transfer to a lower-tier market—is a material delisting risk event. The filing documents the resolution of a listing threat that would materially affect investor assessment of the company's continued exchange listing status.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T13:16:50.768785+00:00","company_name":"Liminatus Pharma, Inc.","ticker":"LIMNW","filing_date":"2026-09-29"}]}